Schulze J, et al. - In patients with primary sclerosing cholangitis (PSC), the researchers estimated the potential of hepatobiliary phase magnetic resonance imaging (MRI) as a parameter for assessment of hepatocellular function. From March 2012 through March 2016, data were collected from one hundred eleven patients with a confirmed diagnosis of PSC who underwent MRI evaluation before and after injection (hepatobiliary phase) of a hepatocyte-specific contrast agent (gadoxetate disodium). They found MRI-measured relative enhancement, using a hepatocyte-specific contrast agent, to identify patients with clinical outcomes with 73.9% sensitivity 92.9% specificity in an analysis of 111 patients with PSC.